Keywords

10.3390/jcm10132914

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

http://orcid.org/0000-0001-8962-4263

Albshesh

Ahmad

Dr. Sheba Medical Center, Tel Hashomer, Israel, Department of Gastroenterology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 52621, Israel ahmad.albshesh@gmail.com Taylor

Joshua

Dr. Department of Gastroenterology, Montreal General Hospital, Montreal, QC 1650, Canada joshua.taylor@mail.mcgill.ca Savarino

Edoardo V.

Dr. Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy edoardosavarino@gmail.com Truyens

Marie

Dr. IBD Unit, Department of Gastroenterology, Ghent University Hospital, 9000 Ghent, Belgium Marie.Truyens@uzgent.be Armuzzi

Alessandro

Dr. IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy alearmuzzi@yahoo.com

http://orcid.org/0000-0002-9421-3087

Ribaldone

Davide G.

Dr. Division of Gastroenterology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy davrib_1998@yahoo.com Shitrit

Ariella Bar-Gil

Dr. Shaare Zedek Medical Center, Faculty of Medicine, Digestive Diseases Institute, Hebrew University of Jerusalem, Jerusalem 9372212, Israel ariellash@szmc.org.il Fibelman

Morine

Dr. Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6423906, Israel morin.fei@gmail.com Molander

Pauliina

Dr. Abdominal Center, Department of Gastroenterology, Helsinki University Hospital, 00101 Helsinki, Finland pauliina.molander@hus.fi Liefferinckx

Claire

Dr. Department of Gastroenterology, Erasme University Hopital, 1070 Brussels, Belgium claire2301@gmail.com Nancey

Stephane

Dr. Department of Gastroenterology, Hospices Civils de Lyon, University Claude Bernard Lyon, 69495 Lyon, France INSERM, U1111, CIRI, 69007 Lyon, France stephane.nancey@chu-lyon.fr Korani

Mohamed

Dr. Division of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester M8 6RB, UK Manchester Academic Health Sciences, University of Manchester, Manchester BL97TD, UK Mohamed.Korani@pat.nhs.uk Rutka

Mariann

Dr. First Department of Medicine, University of Szeged, H-6720 Szeged, Hungary mariannrutka@gmail.com

http://orcid.org/0000-0001-5915-1477

Barreiro-de Acosta

Manuel

Dr. IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago, Spain manubarreiro@hotmail.com Domislovic

Viktor

Dr. Department of Gastroenterology, Hepatology, and Nutrition, University Hospital Centre Zagreb, 10000 Zagreb, Croatia viktor.domislovic@gmail.com Suris

Gerard

Dr. Digestive System Service, Bellvitge University Hospital, Catalan Institute of Health, 08907 Barcelona, Spain tsuris@bellvitgehospital.cat

http://orcid.org/0000-0002-1046-383X

Eriksson

Carl

Dr. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, SE-70182 Örebro, Sweden carl.eriksson@regionorebrolan.se Alves

Catarina

Dr. Department of Gastroenterology, Centro Hospitalar São João, 4200319 Porto, Portugal catarinalves_04@hotmail.com Mpitouli

Afroditi

Dr. Department of Gastroenterology, Venizeleion General Hospital, Heraklion, 71409 Crete, Greece bitouliafro@hotmail.com di Jiang

Caroline

Dr. Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge CB2 0QQ, UK caroline.di.jiang@gmail.com Tepeš

Katja

Dr. University Medical Centre Ljubljana, Department of Gastroenterology, Medical Faculty, University of Ljubljana, 1231 Ljubljana, Slovenia tepes.katja@gmail.com Coletta

Marina

Dr. Department of Hepatology and Clinical Gastroenterology, ASST Santi Paolo e Carlo-Ospedale San Polo Universitario Milano Mariabeatrice, 20142 Milan, Italy marina.coletta@gmail.com

http://orcid.org/0000-0003-0554-5256

Foteinogiannopoulou

Kalliopi

Dr. Department of Gastroenterology, University Hospital of Heraklion, 71500 Crete, Greece drfpopi@hotmail.com

http://orcid.org/0000-0003-2090-3445

Gisbert

Javier P.

Dr. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, 28001 Madrid, Spain javier.p.gisbert@gmail.com Amir-Barak

Hadar

Dr. IBD Center, Division of Gastroenterology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel and the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 49100, Israel Hadar.amir@gmail.com

http://orcid.org/0000-0003-0323-7030

Attauabi

Mohamed

Dr. Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen, 2650 Copenhagen, Denmark mohamed.attauabi.02@regionh.dk Seidelin

Jakob

Dr. Department of Gastroenterology, Herlev University Hospital, 3400 Copenhagen, Denmark jakob.benedict.seidelin@regionh.dk

http://orcid.org/0000-0001-6869-0982

Afif

Waqqas

Dr. Department of Gastroenterology, Montreal General Hospital, Montreal, QC 1650, Canada waqqas.afif@mcgill.ca Marinelli

Carla

Dr. Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy carla.marinelli84@gmail.com

http://orcid.org/0000-0003-1817-7704

Lobaton

Triana

Dr. IBD Unit, Department of Gastroenterology, Ghent University Hospital, 9000 Ghent, Belgium Triana.LobatonOrtega@uzgent.be Pugliese

Daniela

Dr. IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy danielapugliese@gmail.com Maharshak

Nitsan

Dr. Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6423906, Israel nitsanm@tlvmc.gov.il Cremer

Anneline

Dr. Department of Gastroenterology, Erasme University Hopital, 1070 Brussels, Belgium anneline.cremer@erasme.ulb.ac.be Limdi

Jimmy K.

Tamás

Dr. First Department of Medicine, University of Szeged, H-6720 Szeged, Hungary molnar.tamas@med.u-szeged.hu Otero-Alvarin

Borja

Dr. IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago, Spain borja.alvarin@gmail.com

http://orcid.org/0000-0003-3758-4540

Krznaric

Zeljko

Dr. Department of Gastroenterology, Hepatology, and Nutrition, University Hospital Centre Zagreb, 10000 Zagreb, Croatia zeljko.krznaric1@zg.t-com.hr Magro

Fernando

Dr. Department of Gastroenterology, Centro Hospitalar São João, 4200319 Porto, Portugal fernandomagro65@gmail.com Karmiris

Konstantinos

Dr. Department of Gastroenterology, Venizeleion General Hospital, Heraklion, 71409 Crete, Greece kkarmiris@gmail.com Raine

Tim

Dr. Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge CB2 0QQ, UK tim.raine@addenbrookes.nhs.U.K Drobne

David

Dr. University Medical Centre Ljubljana, Department of Gastroenterology, Medical Faculty, University of Ljubljana, 1231 Ljubljana, Slovenia david.drobne@gmail.com Koutroubakis

Ioannis

Dr. Department of Gastroenterology, University Hospital of Heraklion, 71500 Crete, Greece ikoutroubakis@gmail.com

http://orcid.org/0000-0002-9275-4242

Chaparro

Maria

Henit

http://orcid.org/0000-0002-3312-5139

Burisch

Johan

Dr. Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen, 2650 Copenhagen, Denmark burisch@gmail.com Kopylov

Uri

Dr. Sheba Medical Center, Tel Hashomer, Israel, Department of Gastroenterology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 52621, Israel ukopylov@gmail.com

29 06 2021

10 13 23 06 2021

e2914

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

2021

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Keywords Crohn’s disease anti-TNF failure treatment response treatment failure ustekinumab vedolizumab

Journal of Clinical Medicine

J Clin Med

2077-0383

MDPI